New combo attack on sarcoma: immunotherapy meets precision radiation
NCT ID NCT05488366
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This pilot study tests whether combining the immunotherapy drug pembrolizumab with stereotactic ablative radiotherapy (SBRT) is feasible for people with advanced or metastatic soft-tissue sarcoma. Nine participants with disease that cannot be surgically removed will receive both treatments. The main goal is to see if patients can complete the therapy, with secondary goals of measuring tumor response at non-irradiated sites.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (an immunotherapy drug) and stereotactic ablative radiotherapy (focused radiation)
What this could lead to
If this combination works, it could point toward a new treatment option for people with advanced sarcoma that has spread or come back.
What could go wrong
This is a very early, small pilot study with only 9 participants, so results may not apply broadly. The combination may cause side effects from both immunotherapy and radiation, and it is not yet known if it will shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA, SOFT TISSUE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, 92868, United States